Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

BACKGROUND: Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of both pathways may offer greater antitumor activity compared wi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2021
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085979/
https://ncbi.nlm.nih.gov/pubmed/33811482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3880
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires